Related Experiment Videos
Hemoglobinuria detection in 195 urology patients
C W Houston1, G F Jin, S Baron
1Department of Microbiology, University of Texas Medical Branch, Galveston.
Cancer Detection and Prevention
|January 1, 1988
Summary
A new monoclonal antibody ELISA test offers a more sensitive and specific method for detecting hemoglobin in urine, improving diagnosis for bladder and kidney cancer patients. This immunological assay identified more cases, including significant cancer diagnoses missed by traditional dipstick tests.
Area of Science:
- Urology
- Immunology
- Oncology
Background:
- Hematuria detection is crucial for diagnosing bladder and kidney cancer.
- Current chemical tests lack specificity and sensitivity.
- Hemoglobin in urine can indicate urinary tract lesions, including cancers.
Purpose of the Study:
- To develop a specific and sensitive immunological assay for human hemoglobin in urine.
- To compare the performance of a monoclonal antibody ELISA against polyclonal antibody ELISA and dipstick tests.
- To evaluate the diagnostic potential of the new assay for urological cancers.
Main Methods:
- Development of a monoclonal antibody specific for human hemoglobin.
- Creation of a double-antibody biotinylated enzyme-linked immunosorbent assay (ELISA) using the monoclonal antibody (ME).
- Comparison of ME test results with polyclonal antibody ELISA (PE) and dipstick tests in 195 urology patients.
Main Results:
- The monoclonal antibody ELISA (ME) demonstrated significantly higher sensitivity and specificity than the dipstick test.
- The ME test detected hemoglobin in 35% more patients than the dipstick test.
- Four bladder or kidney cancer patients were detected by ME but missed by the dipstick test.
Conclusions:
- The developed monoclonal antibody ELISA is a superior diagnostic tool for detecting hemoglobinuria.
- This assay improves the detection of urological cancers compared to existing methods.
- The assay can detect both normal and abnormal hemoglobin variants in urine.